Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

School-associated measles outbreak driven by vaccination gaps, sociocultural barriers, and delayed detection in Gomba District, Uganda 2025.

Discover public health·2026
Same author

Machine Learning Identifies Potential Accessory Resistance-Associated Mutations in HIV-1 Integrase.

Research square·2026
Same author

Tuberculosis in households with infectious cases in Kampala city: Harnessing health data science for new insights on an ancient disease with persistent, unresolved problems.

PloS one·2026
Same author

Durable viral suppression in the dolutegravir era: a data-enabled, risk-stratified model for integrated HIV care in Uganda.

Frontiers in public health·2026
Same author

AI/ML-based prediction of TB treatment failure: A systematic review and meta-analysis.

medRxiv : the preprint server for health sciences·2026
Same author

Tuberculosis in households with infectious cases in Kampala city: Harnessing health data science for new insights on an ancient disease with persistent, unresolved problems (DS-IAFRICA-TB) Study Protocol.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: May 22, 2026

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Practical guidelines for producing non-replicating canine adenovirus vectors.

Denis Omara1,2,3, Christian Ndekezi1,2,3, Susan Mugaba3

  • 1Uganda Virus Research Institute (UVRI), Entebbe, Uganda.

Plos One
|May 20, 2026
PubMed
Summary

Canine adenovirus type 2 (CAV-2) vectors offer a promising alternative to human adenovirus type 5 (HAdV-5) for vaccine development due to low human seroprevalence. This protocol details the production of non-replicative CAV-2 vectors for translational research.

More Related Videos

Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5
13:17

Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5

Published on: January 28, 2016

An Efficient Method for Adenovirus Production
10:06

An Efficient Method for Adenovirus Production

Published on: June 10, 2021

Related Experiment Videos

Last Updated: May 22, 2026

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5
13:17

Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5

Published on: January 28, 2016

An Efficient Method for Adenovirus Production
10:06

An Efficient Method for Adenovirus Production

Published on: June 10, 2021

Area of Science:

  • Virology
  • Gene Therapy
  • Vaccinology

Background:

  • Adenovirus vectors are efficient gene delivery tools for vaccines and gene therapy.
  • Human adenovirus serotype 5 (HAdV-5) use is limited by pre-existing immunity.
  • Canine adenovirus type 2 (CAV-2) vectors present an alternative with low seroprevalence and efficient gene expression.

Purpose of the Study:

  • To describe a protocol for producing non-replicative canine adenovirus type 2 (CAV-2) vectors.
  • To provide methods for expression, expansion, purification, and titration of CAV-2 vectors.
  • To facilitate the use of CAV-2 vectors in translational research.

Main Methods:

  • Recombinant viral genome release from plasmid DNA.
  • Virus stock expansion in AD-293 cells expressing E1 protein.
  • Purification via ion-exchange chromatography and titration using Improved Kärber method.

Main Results:

  • Successful production of a non-replicative CAV-2 vector.
  • Established methods for purification and titration.
  • Demonstrated feasibility of CAV-2 vector production.

Conclusions:

  • CAV-2 vectors are a viable alternative for vaccine development and gene therapy.
  • The described protocol enables efficient production of CAV-2 vectors.
  • This work supports the advancement of alternative adenoviral vector applications.